MTOR and portal hypertension: To our knowledge, we for the first time demonstrated that the AKT/mTOR signaling pathway was significantly overactivated and mTORC1 rather than mTORC2 was inhibited by rapamycin in the early phase of cirrhotic portal hypertension in rats (Figure 9).